CAMBRIDGE, Mass., Sept. 16, 2011 /PRNewswire/ -- Pathfinder Cell
Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company
focused on the treatment of diseases characterized by
organ-specific cell damage, today announced that effective at the
start of trading today, the ticker symbol for its common stock will
change from SYMD to PFND. The new ticker symbol follows the
recent change of the company's name and has been approved by the
Financial Industry Regulatory Authority.
About Pathfinder Cell Therapy, Inc.
Pathfinder is developing a novel cell-based therapy with the
potential to transform the treatment of diabetes, renal disease,
myocardial infarction, and other diseases characterized by
organ-specific cell damage. Leveraging its internal discovery
of Pathfinder Cells ("PCs") and a proprietary means of isolating
these cells from surrounding tissue, Pathfinder is pioneering a new
field in regenerative medicine. PCs are a newly identified
mammalian cell type present in very low quantities in a variety of
different organs, including the kidney, liver, pancreas, lymph
nodes, and other tissues.
Early studies indicate that PCs stimulate regeneration of
damaged tissues without the cells themselves being incorporated
into the new tissue. The cells appear to be "immune
privileged," and their effects are independent of the tissue source
of PCs. PCs isolated from both rat and human tissue sources
have shown efficacy in animal models of diabetes, cardiac ischemia
and renal reperfusion injury.
For more information please visit:
www.pathfindercelltherapy.com
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements. You
should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are
based on management's current expectations and are subject to a
number of risks and uncertainties, including, but not limited to,
risks related to regulatory approvals and the success of
Pathfinder's ongoing and future studies, including the success of
PCs, and uncertainties relating to the availability of capital to
support Pathfinder's research, development and potential product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies. These and other risks and uncertainties are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission including the
definitive proxy statement filed on July 26,
2011. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
For more information, please contact:
The Ruth Group
Joshua Drumm (investors) /
Victoria Aguiar (media)
(646) 536-7006 / (646) 536-7013
jdrumm@theruthgroup.com / vaguiar@theruthgroup.com
Rick Franklin
Chief Executive Officer
Rick.franklin@pathfindercelltherapy.com
SOURCE Pathfinder Cell Therapy, Inc.
